迪安诊断
(300244)
| 流通市值：78.03亿 | | | 总市值：97.25亿 |
| 流通股本：5.01亿 | | | 总股本：6.25亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 9,258,110,867.57 | 6,218,158,526.59 | 2,973,005,617.76 | 13,408,319,799.56 |
| 营业收入 | 9,258,110,867.57 | 6,218,158,526.59 | 2,973,005,617.76 | 13,408,319,799.56 |
| 二、营业总成本 | 8,491,254,006.48 | 5,720,136,627.66 | 2,776,978,961.2 | 12,243,281,505.07 |
| 营业成本 | 6,661,093,418.77 | 4,496,204,136.58 | 2,214,051,065.03 | 9,213,383,492.55 |
| 税金及附加 | 29,421,498.33 | 20,158,709.56 | 9,942,436.77 | 46,038,218.02 |
| 销售费用 | 876,607,622.37 | 560,495,520.2 | 260,750,513.57 | 1,383,539,384.32 |
| 管理费用 | 547,061,712.54 | 389,705,071.62 | 169,016,190.62 | 947,072,122.85 |
| 研发费用 | 225,278,980.27 | 154,755,056.79 | 72,330,627.47 | 432,640,083.28 |
| 财务费用 | 151,790,774.2 | 98,818,132.91 | 50,888,127.74 | 220,608,204.05 |
| 其中:利息费用 | 155,361,651.96 | 107,100,319.44 | 54,890,718.96 | 250,601,583.16 |
| 其中:利息收入 | 19,408,685.41 | 15,276,537.86 | 10,201,983.42 | 41,762,177.16 |
| 加:公允价值变动收益 | -15,805,135.25 | -16,151,612.59 | -7,475,414.56 | -726,620.39 |
| 加:投资收益 | 9,184,435.86 | 4,965,251.56 | -1,924,989.24 | -17,595,840.52 |
| 资产处置收益 | 2,478,187.96 | 2,916,160.15 | 163,304 | -3,571,427.69 |
| 资产减值损失(新) | 767,410.38 | -2,631,549.9 | -1,452,461.97 | -16,738,382.6 |
| 信用减值损失(新) | -354,350,039.84 | -254,655,991.12 | -92,783,263.47 | -383,080,629.11 |
| 其他收益 | 26,715,565.6 | 15,379,583.16 | 10,304,422.06 | 98,857,469.57 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 435,847,285.8 | 247,843,740.19 | 102,858,253.38 | 842,182,863.75 |
| 加:营业外收入 | 7,838,016.37 | 7,453,010.29 | 2,024,374.56 | 6,643,666.9 |
| 减:营业外支出 | 19,513,681.76 | 8,856,365.66 | 3,516,998.1 | 50,500,537.31 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 424,171,620.41 | 246,440,384.82 | 101,365,629.84 | 798,325,993.34 |
| 减:所得税费用 | 121,487,823.69 | 73,805,833.42 | 24,972,497.21 | 216,735,346.68 |
| 六、净利润 | 302,683,796.72 | 172,634,551.4 | 76,393,132.63 | 581,590,646.66 |
| 持续经营净利润 | 302,683,796.72 | 172,634,551.4 | 76,393,132.63 | 581,590,646.66 |
| 归属于母公司股东的净利润 | 130,856,888.98 | 71,746,812.52 | 23,170,466.54 | 307,461,061.38 |
| 少数股东损益 | 171,826,907.74 | 100,887,738.88 | 53,222,666.09 | 274,129,585.28 |
| (一)基本每股收益 | 0.21 | 0.12 | 0.04 | 0.49 |
| (二)稀释每股收益 | 0.21 | 0.12 | 0.04 | 0.49 |
| 八、其他综合收益 | -1,679.5 | -117.18 | -567.58 | -20,871.95 |
| 归属于母公司股东的其他综合收益 | -1,679.5 | -117.18 | -567.58 | -20,871.95 |
| 九、综合收益总额 | 302,682,117.22 | 172,634,434.22 | 76,392,565.05 | 581,569,774.71 |
| 归属于母公司股东的综合收益总额 | 130,855,209.48 | 71,746,695.34 | 23,169,898.96 | 307,440,189.43 |
| 归属于少数股东的综合收益总额 | 171,826,907.74 | 100,887,738.88 | 53,222,666.09 | 274,129,585.28 |
| 公告日期 | 2024-10-24 | 2024-08-24 | 2024-04-27 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |